Related Experiment Video
Updated: Oct 12, 2025

In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
Photodynamic Therapy Targeting Macrophages Using IRDye700DX-Liposomes Decreases Experimental Arthritis Development
Daphne N Dorst1,2, Marti Boss1, Mark Rijpkema1
1Department of Medical Imaging, Radboudumc, Radboud University, 6525 XZ Nijmegen, The Netherlands.
Abstract:
Macrophages play a crucial role in the initiation and progression of rheumatoid arthritis (RA). Liposomes can be used to deliver therapeutics to macrophages by exploiting their phagocytic ability. However, since macrophages serve as the immune system's first responders, it is inadvisable to systemically deplete these cells. By loading the liposomes with the photosensitizer IRDye700DX, we have developed and tested a novel way to perform photodynamic therapy (PDT) on macrophages in inflamed joints. PEGylated liposomes were created using the film method and post-inserted with micelles containing IRDye700DX. For radiolabeling, a chelator was also incorporated. RAW 264.7 cells were incubated with liposomes with or without IRDye700DX and exposed to 689 nm light. Viability was determined using CellTiterGlo. Subsequently, biodistribution and PDT studies were performed on mice with collagen-induced arthritis (CIA). PDT using IRDye700DX-loaded liposomes efficiently induced cell death in vitro, whilst no cell death was observed using the control liposomes. Biodistribution of the two compounds in CIA mice was comparable with excellent correlation of the uptake with macroscopic and microscopic arthritis scores. Treatment with 700DX-loaded liposomes significantly delayed arthritis development. Here we have shown the proof-of-principle of performing PDT in arthritic joints using IRDye700DX-loaded liposomes, allowing locoregional treatment of arthritis.
Insights
This study introduces a new photodynamic therapy (PDT) using IRDye700DX-loaded liposomes to target macrophages in rheumatoid arthritis (RA) joints. This locoregional treatment effectively reduces inflammation and delays arthritis progression.
Area of Science:
- Immunology
- Nanomedicine
- Photochemistry
Background:
- Macrophages are key drivers in rheumatoid arthritis (RA) pathogenesis.
- Targeting macrophages is a therapeutic strategy, but systemic depletion is undesirable.
- Liposomes offer a method for targeted drug delivery to macrophages.
Purpose of the Study:
- To develop and evaluate a novel photodynamic therapy (PDT) for locoregional treatment of macrophages in inflamed joints.
- To utilize IRDye700DX-loaded liposomes for targeted PDT in rheumatoid arthritis.
- To assess the efficacy and safety of this approach in vitro and in vivo.
Main Methods:
- PEGylated liposomes loaded with IRDye700DX were prepared.
- RAW 264.7 cells were treated with liposomes and exposed to light for in vitro viability assays.
- Biodistribution and PDT studies were conducted in mice with collagen-induced arthritis (CIA).
Main Results:
- IRDye700DX-loaded liposomes induced efficient cell death in macrophages in vitro.
- Biodistribution studies showed comparable uptake correlating with arthritis severity.
- PDT treatment significantly delayed the onset and progression of arthritis in CIA mice.
Conclusions:
- This study demonstrates the proof-of-principle for locoregional PDT in arthritic joints using IRDye700DX-loaded liposomes.
- This approach allows targeted treatment of macrophages, offering a potential new strategy for rheumatoid arthritis.
- The findings support the development of liposomal PDT for localized inflammatory joint diseases.
More Related Videos
09:18Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017